A method for predicting an immunological response of a test subject to an immunotherapy, comprising: amplifying nucleic acid sequences from one or more solid tumor samples comprising lymphoid cells, wherein the samples are obtained from the test subject at one or more time points prior to and after treatment with said immunotherapy, and wherein the nucleic acid sequences are amplified in a multiplex PCR assay using a plurality of adaptive immune receptor V-segment oligonucleotide primers and either a plurality of AIR J-segment oligonucleotide primers or one or more AIR C-segment oligonucleotide primers; obtaining nucleic acid sequence information from the amplified nucleic acid sequences, wherein said nucleic acid sequence information comprises sequences for a plurality of unique rearranged nucleic acid sequences, each encoding an adaptive immune receptor polypeptide; quantifying an AIR sequence diversity score for said one or more solid tumor samples based on the total number of unique rearranged DNA sequences in said one or more solid tumor samples, wherein said AIR sequence diversity score is quantified using said nucleic acid sequence information; quantifying an AIR sequence distribution score for said one or more solid tumor samples by calculating a frequency of occurrence of a plurality of unique rearranged DNA sequences in said one or more solid tumor samples, wherein said AIR sequence distribution score is quantified using said nucleic acid sequence information; determining a test subject rating score for said one or more solid tumor samples based on said AIR sequence diversity score and said AIR sequence distribution score; comparing said test subject rating score with a control subject rating score obtained from a sample from a control subject with a known response to said immunotherapy; and predicting an immunological response for said test subject to said immunotherapy based on said comparison. amplifying nucleic acid sequences from one or more solid tumor samples comprising lymphoid cells, wherein the samples are obtained from the test subject at one or more time points prior to and after treatment with said immunotherapy, and wherein the nucleic acid sequences are amplified in a multiplex PCR assay using a plurality of adaptive immune receptor V-segment oligonucleotide primers and either a plurality of AIR J-segment oligonucleotide primers or one or more AIR C-segment oligonucleotide primers; obtaining nucleic acid sequence information from the amplified nucleic acid sequences, wherein said nucleic acid sequence information comprises sequences for a plurality of unique rearranged nucleic acid sequences, each encoding an adaptive immune receptor polypeptide; quantifying an AIR sequence diversity score for said one or more solid tumor samples based on the total number of unique rearranged DNA sequences in said one or more solid tumor samples, wherein said AIR sequence diversity score is quantified using said nucleic acid sequence information; quantifying an AIR sequence distribution score for said one or more solid tumor samples by calculating a frequency of occurrence of a plurality of unique rearranged DNA sequences in said one or more solid tumor samples, wherein said AIR sequence distribution score is quantified using said nucleic acid sequence information; determining a test subject rating score for said one or more solid tumor samples based on said AIR sequence diversity score and said AIR sequence distribution score; comparing said test subject rating score with a control subject rating score obtained from a sample from a control subject with a known response to said immunotherapy; and predicting an immunological response for said test subject to said immunotherapy based on said comparison.